IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4497
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$63M
Geert R. Kersten
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for head and neck cancer. Its Ligand Epitope Antigen Presentation System stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$CVM CEL SCI CORP | 30 | 16 | 11 | 55 | - | - | -122.3% | -59.5% | - | - | - | - | 0.0% | 106.0x | $63M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
CEL SCI CORP (CVM) receives a "Avoid" rating with a composite score of 30.4/100. It ranks #4497 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Geert R. Kersten
Chief Executive Officer
Labor Force
43
16
29
32
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for CVM
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CVM.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -122.3% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 11yr history
Interest coverage -61.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags CEL SCI CORP with an Avoid rating, assigning a composite score of 30.4/100 and 1 out of 5 stars. Ranked #4497 of 7,333 stocks, CVM falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CEL SCI CORP registers a weak quality score of just 16/100, indicating significant profitability challenges. The company reports a return on equity of -122.3% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
CVM registers a value score of just 11/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.62x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
CEL SCI CORP's investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -59.5% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CVM demonstrates moderate momentum with a score of 55/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of -1.93 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
CVM's stability score of 32/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of -1.93 and a debt-to-equity ratio of 106.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
CEL SCI CORP's short interest score of 23/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 106.00x), micro-cap liquidity risk. At $63M (micro-cap), CVM carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
CEL SCI CORP is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4497 of 7,333 overall (39th percentile). Key comparisons include ROE of -122.3% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CVM currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (11) would have the largest impact on the composite score.
ROE 4832% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 52900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate CEL SCI CORP (CVM) as Avoid with a composite score of 30.4/100 at a current price of $4.57. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (55th percentile) and stability (32th percentile), which together account for the majority of the composite score. Offsetting weakness in value (11th percentile) and quality (16th percentile) tempers our overall conviction. We assign a No Moat rating (23/100), High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is widening, which provides additional comfort in the durability of the competitive position.
CEL SCI CORP holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.4/100 places it at rank #4497 in our full 7,333-stock universe. At $63M in market capitalization, CEL SCI CORP is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (55th percentile) are neutral regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for CEL SCI CORP, which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $4.57, CEL SCI CORP is trading at a premium to fundamental value. Our value factor score of 11/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 3.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 30.4/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (106% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Below-average quality (16th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a High uncertainty rating to CEL SCI CORP. Key risk factors include significant leverage (106% debt-to-equity), below-average price stability (32th percentile), weak quality scores (16th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: significant leverage (106% debt-to-equity); below-average price stability (32th percentile); weak quality scores (16th percentile); low beta of -1.93 — while defensive, this may indicate limited upside participation in bull markets. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 32th percentile and quality factor at the 16th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate CEL SCI CORP's capital allocation as Poor. Key concerns include low returns on equity (-122.3%), weak asset returns (ROA -59.5%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — CEL SCI CORP significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, CEL SCI CORP receives a Avoid rating with a composite score of 30.4/100 (rank #4497 of 7,333). Our quantitative framework assigns a No Moat (23/100, trend: widening), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on CEL SCI CORP at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign CEL SCI CORP a meaningful economic moat, scoring 23/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 12.5/20.
The strongest moat sources are margin superiority (12.5/20) and growth durability (7.5/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Rev growth N/A, 11yr history. These pillars form the core of CEL SCI CORP's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (0/20). ROE proxy -122.3% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Widening. ROIC has trended upward at ~577.3pp per year, and operating margin trajectory confirms strengthening economics. CEL SCI CORP's competitive position is improving on a fundamental basis. We expect the moat score to drift upward if these trends persist over the next 12–18 months.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 16/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -122.3% and ROA of -59.5%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -122.3% compares to a sector median of -2.5%.
The balance sheet reflects above-average leverage with D/E of 106%. The sector median D/E is 0%, putting CEL SCI CORP at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20 per unit. U Power shares dipped 54% to $0.7090 on Monday. Here are some other stocks moving in today's mid-day session. Gainers EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares jumped 211.3% to $20.58 after the company announced the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieved all primary and secondary endpoints. Hawaiian Holdings, Inc. (NASDAQ: HA) shares climbed 187% to $14.03 after Alaska Air Group, Inc. (NYSE: ALK) announced plans to acquire the company in a deal worth $1.9 billion. Alterity Therapeutics Limited (NASDAQ: ATHE) shares climbed 156% to $4.25 after the company announced that ATHE434 new data in a Parkinson's disease primate model were presented at the Future of Parkinson's Disease Conference 2023. SilverSun Technologies, Inc. (NASDAQ: SSNT) gained 142.7% to $8.91 after the company announced Jacobs Private Equity II and minority co-investors will invest $1 billion in the company. Bit Brother Limited (NASDAQ: BETS) rose 86.3% to $0.0723 after surging 43% on Friday. Bit Brother said it purchased 3300 units of Antminer S19 miners, injecting powerful momentum into its Bitcoin mining operations. Lucy Scientific Discovery Inc. (NASDAQ: LSDI) shares jumped 72.2% to $0.3530. View, Inc. (NASDAQ: VIEW) gained 52.3% to $1.5701. Mawson Infrastructure Group, Inc. (NASDAQ: MIGI) rose 29.8% to $1.17. Marpai, Inc. (NASDAQ: MRAI) jumped 28.3% to $1.9250. CEL-SCI Corporation (NYSE: CVM) surged 25.6% to $2.6009. The UK'S National Institute for Health and Care Excellence selected CEL-SCI's Multikine as a potential new ...
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring. The Singing Machine Company, Inc. (NASDAQ: MICS) shares surged 32% to $2.10 after the company announced it launched a new party accessory product line available at Walmart. Biophytis S.A. (NASDAQ: BPTS) gained 29% to $2.78 after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product. iCAD, Inc. (NASDAQ: ICAD) rose 21.3% to $2.50. iCAD signed strategic commercial agreement with Radiology Partners, the nation's largest radiology practice. Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares climbed 18.7% to $0.3121 after EMA announced positive feedback on the company's proposed Phase 3 study AR-301 for pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients. Interlink Electronics, Inc. (NASDAQ: LINK) shares climbed 17.4% to $12.65. Innodata Inc. (NASDAQ: INOD) gained 16.2% to $12.43. D-Wave Quantum Inc. (NYSE: QBTS) climbed 15.1% to $2.9585. Benchmark, on Monday, maintained a Buy rating on the stock and raised its price target from $2 to $3. Advent Technologies Holdings, Inc. (NASDAQ: ADN) gained 14.4% to $0.9595. Advanced Emissions Solutions, Inc. (NASDAQ: ADES) rose 13.4% to $1.8061. Advanced Emissions Solutions named Robert Rasmus to succeed Greg Marken as President and CEO on July 17, 2023. Healthcare Triangle, Inc. (NASDAQ: HCTI) gained 13.4% to $5.26 in pre-market trading after jumping 27% on Monday. Altice USA, Inc. ...
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product. Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares gained 41.8% to $0.3729 in pre-market trading after EMA announced positive feedback on the company's proposed Phase 3 study AR-301 for pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients. Karyopharm Therapeutics Inc. (NASDAQ: KPTI) rose 26.1% to $1.93 in pre-market trading after the company received FDA Fast Track Designation for Selinexor for Myelofibrosis. Rubicon Technologies, Inc. (NYSE: RBT) shares rose 19.9% to $0.47 in pre-market trading after surging 19% on Monday. Taoping Inc. (NASDAQ: TAOP) shares gained 14.4% to $0.5999 in pre-market trading after declining 7% on Monday. Vapotherm, Inc. (NYSE: VAPO) shares rose 13.4% to $0.4364 in pre-market trading after gaining 8% on Monday. Healthcare Triangle, Inc. (NASDAQ: HCTI) gained 13.4% to ...
Gainers Leju Holdings Limited (NYSE: LEJU) gained 103.7% to $7.25 in pre-market trading after jumping around 97% on Monday . Hour Loop, Inc. (NASDAQ: HOUR) shares climbed 93.5% to $3.25 in pre-market trading. EF Hutton recently downgraded Hour Loop from Buy to Hold and lowered the price target from $5 to $2. AGBA Group Holding Limited (NASDAQ: AGBA) climbed 80.6% to $3.65 in pre-market trading after dropping over 12% on Monday. Tian Ruixiang Holdings Ltd (NASDAQ: TIRX) gained 75.6% to $3.83 in pre-market trading after jumping around 34% on Monday. Wah Fu Education Group Limited (NASDAQ: WAFU) surged 47.6% to $4.00 in pre-market trading after gaining 27% on Monday. Huize Holding Limited (NASDAQ: HUIZ) gained 42.4% to $2.05 in pre-market trading after gaining over 15% on Monday. CEL-SCI Corporation (NYSE: CVM) jumped 31.4% ...
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. Altamira Therapeutics Ltd. (NASDAQ: CYTO) shares jumped 52.7% to $3.59 after the company said data from a recent peer-reviewed clinical study demonstrated Bentrio's superior nasal residence time and rheological properties. Lavoro Limited (NASDAQ: LVRO) gained 44.7% to $13.86. Lavoro and TPB Acquisition Corporation I announced completion of business combination. HUB Cyber Security (Israel) Ltd. (NASDAQ: HUBC) rose 36.6% to $1.71 after dipping 21% on Thursday. Seer, Inc. (NASDAQ: SEER) gained 35% to $5.68 after the company reported better-than-expected Q4 EPS and sales results. ETAO International Co., Ltd. (NASDAQ: ETAO) jumped 33% to $2.0294. Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) gained 30.3% to $3.5569. Bullfrog AI recently priced its IPO at $6.50 per share. Ardelyx, Inc. (NASDAQ: ARDX) surged 28% to $3.70 after the company reported better-than-expected Q4 sales results. C3.ai, Inc. (NYSE: AI) shares jumped 24.3% to $26.48 after the company reported better-than-expected Q3 results and issued strong guidance. Genius Group Limited (NYSE: GNS) gained 24.3% to $2.8340. Jianzhi Education Technology Group Company Limited (NASDAQ: JZ) gained 23% to $1.39. Heritage Insurance Holdings, Inc. (NASDAQ: HRTG) rose 22.2% to $3.3224 after posting Q4 results. Samsara Inc. (NYSE: IOT) gained 21.7% to $20.55 after the company reported better-than-expected Q4 results and issued strong guidance. Velo3D, Inc. (NYSE: VLD) rose 20.5% to $3.4094 after the company reported better-than-expected Q4 adjusted EPS and sales results. Rubius Therapeutics, Inc. (NASDAQ: RUBY) gained 19.8% to $0.1360. Rubius Therapeutics recently outlined dissolution plan, after unsuccessful attempt on alternatives. Xos, Inc. (NASDAQ: XOS) jumped 19% to $0.7894. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) ...